Reata Pharma (RETA) Tops Q2 EPS by 75c

Reata Pharma (NASDAQ: RETA) reported Q2 EPS of ($1.36), $0.75 better than the analyst estimate of ($2.11). Revenue for the quarter came in at $762 thousand versus the consensus estimate of $1.55 million.

For earnings history and earnings-related data on Reata Pharma (RETA) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Southland Holdings (SLND) Misses Q2 EPS by 122c
• Lumexa Imaging Holdings, Inc. (LMRI) Reports In-Line Q2 EPS; Offers Guidance